Roivant to present Phase 2 study results for PH-ILD drug at ERS Congress

Roivant Sciences will present top-line results from the Phase 2 PHocus Study of Mosliciguat for pulmonary hypertension associated with interstitial lung disease at the ERS Congress 2026.

6 Sept, 05:14 — 6 Sept, 05:14

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual3d ago

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call - Taiwan News

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Taiwan News

Read full article →

Roivant to present Phase 2 study results for PH-ILD drug at ERS Congress

Sources

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call - Taiwan News

Related Stories

EU grants Spain €115m aid as documents reveal intelligence warnings before Ceuta migrant crisis

Israeli Foreign Minister Rules Out Expelling Palestinians from Gaza

Zelensky’s Plane Dodges Drone Near Oslo; Israel Denies Gaza Expulsions

British man charged with assisting Russian intelligence in sabotage plot